Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Defining Breadth of Hepatitis C Virus Neutralization.

Kinchen VJ, Bailey JR.

Front Immunol. 2018 Aug 2;9:1703. doi: 10.3389/fimmu.2018.01703. eCollection 2018. Review.

2.

Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.

Wasilewski LN, Ray SC, Bailey JR.

J Gen Virol. 2016 Nov;97(11):2883-2893. doi: 10.1099/jgv.0.000608. Epub 2016 Sep 21.

3.

A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.

Urbanowicz RA, McClure CP, Brown RJ, Tsoleridis T, Persson MA, Krey T, Irving WL, Ball JK, Tarr AW.

J Virol. 2015 Dec 23;90(7):3288-301. doi: 10.1128/JVI.02700-15.

4.

Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.

Law JLM, Logan M, Wong J, Kundu J, Hockman D, Landi A, Chen C, Crawford K, Wininger M, Johnson J, Mesa Prince C, Dudek E, Mehta N, Tyrrell DL, Houghton M.

J Virol. 2018 May 14;92(11). pii: e02141-17. doi: 10.1128/JVI.02141-17. Print 2018 Jun 1.

5.

Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms.

Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE Jr, Bailey JR.

Proc Natl Acad Sci U S A. 2018 Jan 2;115(1):E82-E91. doi: 10.1073/pnas.1718441115. Epub 2017 Dec 18.

6.

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.

Hraber P, Rademeyer C, Williamson C, Seaman MS, Gottardo R, Tang H, Greene K, Gao H, LaBranche C, Mascola JR, Morris L, Montefiori DC, Korber B.

J Virol. 2017 Sep 12;91(19). pii: e00991-17. doi: 10.1128/JVI.00991-17. Print 2017 Oct 1. Erratum in: J Virol. 2017 Dec 14;92 (1):.

7.

A Hepatitis C Virus Envelope Polymorphism Confers Resistance to Neutralization by Polyclonal Sera and Broadly Neutralizing Monoclonal Antibodies.

Wasilewski LN, El-Diwany R, Munshaw S, Snider AE, Brady JK, Osburn WO, Ray SC, Bailey JR.

J Virol. 2016 Jan 27;90(7):3773-82. doi: 10.1128/JVI.02837-15.

8.

Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.

Cohen YZ, Lorenzi JCC, Seaman MS, Nogueira L, Schoofs T, Krassnig L, Butler A, Millard K, Fitzsimons T, Daniell X, Dizon JP, Shimeliovich I, Montefiori DC, Caskey M, Nussenzweig MC.

J Virol. 2018 Feb 12;92(5). pii: e01883-17. doi: 10.1128/JVI.01883-17. Print 2018 Mar 1.

9.

A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.

Desombere I, Mesalam AA, Urbanowicz RA, Van Houtte F, Verhoye L, Keck ZY, Farhoudi A, Vercauteren K, Weening KE, Baumert TF, Patel AH, Foung SKH, Ball J, Leroux-Roels G, Meuleman P.

Antiviral Res. 2017 Dec;148:53-64. doi: 10.1016/j.antiviral.2017.10.015. Epub 2017 Oct 23.

10.

Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance.

Bailey JR, Wasilewski LN, Snider AE, El-Diwany R, Osburn WO, Keck Z, Foung SK, Ray SC.

J Clin Invest. 2015 Jan;125(1):437-47. doi: 10.1172/JCI78794. Epub 2014 Dec 15.

11.

Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV Infection.

Swann RE, Cowton VM, Robinson MW, Cole SJ, Barclay ST, Mills PR, Thomson EC, McLauchlan J, Patel AH.

J Virol. 2016 Apr 14;90(9):4530-4543. doi: 10.1128/JVI.02669-15. Print 2016 May.

12.

Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J.

Hepatology. 2014 Nov;60(5):1551-62. doi: 10.1002/hep.27298. Epub 2014 Oct 2.

13.

Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization.

Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, Frey SE, Belshe RB, Tyrrell DL, Law JL, Houghton M.

J Virol. 2014 Dec;88(24):14278-88. doi: 10.1128/JVI.01911-14. Epub 2014 Oct 1.

14.

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL.

J Biol Chem. 2006 Jul 7;281(27):18285-95. Epub 2006 May 4.

15.

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.

Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T.

Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.

PMID:
23673355
16.

Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.

Kilgore KM, Murphy MK, Burton SL, Wetzel KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, Cole KS, Villinger F, Robinson JE, Pulendran B, Hunter E, Collman RG, Amara RR, Derdeyn CA.

J Virol. 2015 Aug;89(16):8130-51. doi: 10.1128/JVI.01221-14. Epub 2015 May 27.

17.

Broad neutralization of hepatitis C virus-resistant variants by Civacir hepatitis C immunoglobulin.

Tawar RG, Heydmann L, Bach C, Schüttrumpf J, Chavan S, King BJ, McClure CP, Ball JK, Pessaux P, Habersetzer F, Bartenschlager R, Zeisel MB, Baumert TF.

Hepatology. 2016 Nov;64(5):1495-1506. doi: 10.1002/hep.28767. Epub 2016 Sep 30.

PMID:
27531416
18.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

19.

Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate.

Keck ZY, Xia J, Wang Y, Wang W, Krey T, Prentoe J, Carlsen T, Li AY, Patel AH, Lemon SM, Bukh J, Rey FA, Foung SK.

PLoS Pathog. 2012;8(4):e1002653. doi: 10.1371/journal.ppat.1002653. Epub 2012 Apr 12.

20.

Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.

Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuisson J, Persson MA.

Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):16269-74. Epub 2007 Oct 2.

Supplemental Content

Support Center